このエントリーをはてなブックマークに追加
ID 69431
フルテキストURL
suppl.pdf 224 KB
著者
Nishimura, Shingo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Inoue, Shota Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sekito, Takanori Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
Tsuboi, Ichiro Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tokunaga, Moto Department of Urology, NHO Okayama Medical Center
Yoshinaga, Kasumi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Maruyama, Yuki Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
Mitsui, Yosuke Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamanoi, Tomoaki Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawada, Tatsushi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kubota, Risa Department of Urology, NHO Okayama Medical Center
Sadahira, Takuya Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID researchmap
Tominaga, Yusuke Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Iwata, Takehiro Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID
Katayama, Satoshi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Bekku, Kensuke Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Edamura, Kohei Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Wada, Koichiro Department of Urology, Shimane University Faculty of Medicine
Kobayashi, Yasuyuki Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Araki, Motoo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
抄録
Background/Objectives: Limited research exists on risk factors for urinary tract infections (UTIs) in kidney transplant recipients, particularly in high-risk groups such as ABO-incompatible or donor-specific antibody (DSA)-positive cases. Early UTIs, especially within the first month post-transplant, impact on acute rejection and long-term graft outcomes, highlighting the need for risk factor identification and management. Methods: Among 157 living donor kidney transplant cases performed at our institution between 2009 and 2024, 128 patients were included after excluding cases with >72 h of perioperative prophylactic antibiotics or urological complications. UTI was defined as the presence of pyuria and a positive urine culture, accompanied by clinical symptoms requiring antibiotic treatment, occurring within one month post-transplantation. Results: The median onset of UTI was postoperative day 8 (interquartile range, IQR: 6.8–9.3). No subsequent acute rejection episodes were observed. The median serum creatinine at 1 month postoperatively was 1.3 mg/dL (IQR: 1.1–1.7), and this was not significantly different from those who did not develop UTI. In univariate analysis, low or high BMI (<20 or >25), longer dialysis duration (>2.5 years), desensitization therapy (plasmapheresis + rituximab), elevated preoperative neutrophil-to-lymphocyte ratio (NLR) (≥3), and longer warm ischemic time (WIT) (≥7.8 min) were significantly associated with an increased infection risk of UTI (p = 0.010, 0.036, 0.028, 0.015, and 0.038, respectively). Multivariate analyses revealed that abnormal BMI, longer dialysis duration, desensitization therapy, and longer WIT were independent risk factors for UTI (p = 0.012, 0.031, 0.008, and 0.033, respectively). The incidence of UTI increased with the number of risk factors: 0% (0/16) for zero, 10% (5/48) for one, 31% (16/51) for two, 45% (5/11) for three, and 100% (2/2) for four risk factors. Conclusions: Desensitization therapy, BMI, dialysis duration, and WIT were identified as independent risk factors for perioperative UTI. In patients with risk factors, additional preventive strategies should be considered, with extended antibiotic prophylaxis being one potential option.
キーワード
living donor kidney transplantation
urinary tract infection
perioperative
desensitization
rituximab
plasmapheresis
body mass index
dialysis duration
warm ischemic time
prophylactic antimicrobials
発行日
2025-08-28
出版物タイトル
Journal of Clinical Medicine
14巻
17号
出版者
MDPI AG
開始ページ
6102
ISSN
2077-0383
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2025 by the authors.
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.3390/jcm14176102
ライセンス
https://creativecommons.org/licenses/by/4.0/
Citation
Nishimura, S.; Inoue, S.; Sekito, T.; Tsuboi, I.; Tokunaga, M.; Yoshinaga, K.; Maruyama, Y.; Mitsui, Y.; Yamanoi, T.; Kawada, T.; et al. Risk Factors for Perioperative Urinary Tract Infection After Living Donor Kidney Transplantation Characterized by High Prevalence of Desensitization Therapy: A Single-Center Analysis. J. Clin. Med. 2025, 14, 6102. https://doi.org/10.3390/jcm14176102